Seres Therapeutics
MCRB
74 hedge funds and large institutions have $341M invested in Seres Therapeutics in 2017 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 27 increasing their positions, 23 reducing their positions, and 14 closing their positions.
234% more call options, than puts
Call options by funds: $1.3M | Put options by funds: $390K
17% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 23
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.04% less ownership
Funds ownership: 3.78% → 3.74% (-0.04%)
1% less capital invested
Capital invested by funds: $344M → $341M (-$2.68M)
6% less funds holding
Funds holding: 79 → 74 (-5)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.53M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$1.39M |
| 3 |
Renaissance Technologies
New York
|
+$1.12M |
| 4 |
State Street
Boston,
Massachusetts
|
+$353K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$337K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.59M |
| 2 |
JP Morgan Chase
New York
|
-$1.06M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$743K |
| 4 |
SIM
Spark Investment Management
New York
|
-$613K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$582K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
| – | -$427K | -1,893 | Closed |
|
|
OAM
77
Oxford Asset Management
Oxford,
United Kingdom
| – | -$259K | -1,151 | Closed |
|
|
HIM
78
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
| – | -$238K | -1,055 | Closed |
|
79
TD Asset Management
Toronto,
Ontario, Canada
| – | -$171K | -759 | Closed |
|
|
HLA
80
Hamilton Lane Advisors
Conshohocken,
Pennsylvania
| – | -$168K | -744 | Closed |
|
|
OPPM
81
Opus Point Partners Management
New York
| – | -$158K | -700 | Closed |
|
|
FRM
82
Fox Run Management
Greenwich,
Connecticut
| – | -$136K | -605 | Closed |
|
|
ARTA
83
A.R.T. Advisors
New York
| – | -$132K | -588 | Closed |
|
|
EMG
84
Ellington Management Group
Old Greenwich,
Connecticut
| – | -$119K | -530 | Closed |
|
|
AIM
85
Acrospire Investment Management
Chicago,
Illinois
| – | -$50K | -224 | Closed |
|
86
Acadian Asset Management
Boston,
Massachusetts
| – | -$30K | -133 | Closed |
|
|
SF
87
Synovus Financial
Columbus,
Georgia
| – | -$15K | -64 | Closed |
|
MCRB Hedge Fund Activity: Q2 2017 in Review
74 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q2 2017, worth a combined $341M — down 0.78% from $344M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of MCRB and 9 opened new positions — a net loss of 5 holders — while 23 trimmed existing stakes and 27 added.
The largest buyer was BlackRock, adding an estimated $1.53M. The largest seller was T. Rowe Price Associates, cutting an estimated $2.59M.
- 74 institutional investors held Seres Therapeutics (MCRB) as of Q2 2017, down from 79 in Q1 2017.
- Funds reported $341M of Seres Therapeutics stock for Q2 2017, down 0.78% quarter-over-quarter.
- 9 funds opened new Seres Therapeutics positions in Q2 2017 and 14 closed out, a net change of -5 holders.
- The largest Seres Therapeutics buyer in Q2 2017 was BlackRock, an estimated $1.53M added.
- The largest Seres Therapeutics seller in Q2 2017 was T. Rowe Price Associates, an estimated $2.59M sold.
Based on aggregated 13F filings for Q2 2017.